|Name of listed company:||Chugai Pharmaceutical Co., Ltd.|
|Code number:||4519 (1st Section of Tokyo Stock Exchange)|
|Head office:||1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo|
|President & CEO:||Tatsuro Kosaka|
|Inquiries to:||Masahiko Uchida,|
|General Manager, Corporate Communications Dept.|
TOKYO, May 29, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the Tokyo District Court has rendered judgment dismissing the plaintiff’s claim in the lawsuit filed by Genentech Inc., wherein the plaintiff demands prohibition against sales etc. of the biosimilar product of anti-CD20 monoclonal antibody Rituxan® Intravenous Infusion 100 mg and 500 mg (Rituxan Intravenous Infusion) by Sandoz K.K. and Kyowa Hakko Kirin Co., Ltd., citing such parties' infringement of three use patents owned by Biogen Inc., as the ground.
Chugai and Zenyaku Kogyo Co., Ltd. have been assisting intervention in the lawsuit.
Biogen is a holder of those patents and Genentech Inc. is the exclusive licensee. Zenyaku Kogyo is the exclusive distribution rights' holder in Japan of Rituxan Intravenous Infusion, and Chugai is the joint distributor of Rituxan Intravenous Infusion with Zenyaku Kogyo.
There is no impact expected on Chugai’s financial prospects for this matter at this stage.
Trademarks used or mentioned in this release are protected by law.